TFRC and neoplasm: In the study by Kuang [58], DGL-PEG-T7 [dendrigraft poly-l-lysines polyethylene glycol–peptide T7 (sequence His-Ala-Lle-Tyr-Pro-Arg-His)]/shVEGF could inhibit VEGF mRNA due to the T7 peptide that binds transferrin receptor (TfR) on the surface of the tumor cell, and the shVEGF subunit in the nanocomplex allowed DOX to inhibit tumor growth and angiogenesis.